Ronomilast

Ronomilast (previously known as ELB353 or AWD 12353) is a third-generation, orally administered phosphodiesterase-4 (PDE4) inhibitor developed for the treatment of chronic inflammatory disorders. Its primary mechanism of action is the inhibition of type 4 cyclic nucleotide phosphodiesterase (PDE4), which leads to anti-inflammatory effects. Ronomilast was investigated mainly for chronic obstructive pulmonary disease (COPD) and hypersensitivity conditions. The drug originated from Biotie Therapies' proprietary PDE technology platform and was later developed by Acorda Therapeutics. Clinical development included phase I studies in healthy volunteers to assess safety and pharmacokinetics; however, further development was discontinued following company bankruptcy[1][2][3][4][5].

Other names

ronomilastELB 353ELB353ELB-353AWD 12353AWD12353AWD-12353